Could Karyopharm Therapeutics Inc (KPTI) Change Direction After Today’s Significant Increase?

September 17, 2017 - By Nellie Frank

Investors sentiment increased to 2.4 in Q4 2016. Its up 0.88, from 1.52 in 2016Q3. It is positive, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.
Thomas J Herzfeld, a Florida-based fund reported 4,868 shares. 75,900 are held by Utd Svcs Automobile Association. Proshare Ltd Llc holds 31,601 shares. Dimensional Fund Advsr L P has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 412,376 were accumulated by Jpmorgan Chase. Parametric Port Ltd Liability has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Geode Capital Mgmt Ltd Company holds 0% or 156,493 shares. State Street holds 0% or 406,103 shares. Vanguard Gp accumulated 1.13 million shares. Goldman Sachs Gp reported 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Susquehanna Group Limited Liability Partnership accumulated 0% or 38,492 shares. Ny State Common Retirement Fund accumulated 0% or 29,430 shares. Bancshares Of America De reported 45,819 shares. Moreover, Citadel Advsrs has 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Trexquant L P, Connecticut-based fund reported 29,007 shares.

The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! The stock increased 4.07% or $0.43 on September 15, reaching $11. About 432,710 shares traded or 146.40% up from the average. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.
The move comes after 7 months positive chart setup for the $518.53M company. It was reported on Sep, 17 by We have $11.99 PT which if reached, will make NASDAQ:KPTI worth $46.67 million more.

Investors wait Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report on November, 6. its quarterly earnings Wall Street analysts expect $-0.64 EPS, up $0.05 or 7.25 % from last year’s $-0.69 same quarter earnings. Karyopharm Therapeutics Inc’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.64 EPS reproted in the previous quarter,

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. On Thursday, August 18 the stock rating was initiated by H.C. Wainwright with “Buy”. Jefferies maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, March 15 with “Hold” rating. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) earned “Hold” rating by Jefferies on Wednesday, January 6. The rating was maintained by Jefferies with “Buy” on Monday, September 11. Canaccord Genuity initiated Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, December 22 with “Buy” rating. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Buy” rating on Tuesday, August 8 by Canaccord Genuity. Jefferies initiated Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Wednesday, September 9 with “Buy” rating. On Tuesday, March 15 the stock rating was downgraded by Bank of America to “Underperform”. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Overweight” rating given on Monday, March 14 by JP Morgan.

More notable recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: which released: “Karyopharm Therapeutics (KPTI) Names Michael Falvey as Chief Financial Officer” on September 12, 2017, also with their article: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q2 2017 Results …” published on August 08, 2017, published: “US FDA Division of Hematology Products Lifts Partial Clinical Hold on …” on March 30, 2017. More interesting news about Karyopharm Therapeutics Inc (NASDAQ:KPTI) were released by: and their article: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” published on June 30, 2017 as well as‘s news article titled: “Karyopharm Therapeutics (KPTI) Presents Selinexor and KPT-9274 Clinical Data …” with publication date: September 08, 2017.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $518.53 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.